Zhejiang Conba Pharmaceutical Co., Ltd. Class ASSE: 600572

"Zhejiang CONBA Pharmaceutical Co., Ltd."Announcement on the Subsidiary's Rivaroxaban Tablets Obtaining Supplementary Approval for Additional Specifications and Other Matters

Jul 14, 2026 · Issued by Zhejiang Conba Pharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange

Announcement on the Subsidiary's Rivaroxaban Tablets Obtaining Supplementary Approval for Additional Specifications and Other Matters

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Earlier from Zhejiang Conba Pharmaceutical Co., Ltd. Class A

"Zhejiang CONBA Pharmaceutical Co., Ltd."Announcement on Inclusion of Products of the Company and Its Subsidiaries in the "National Essential Medicines List (2026 Edition)"Jul 11
"Zhejiang CONBA Pharmaceutical Co., Ltd."Announcement on the Execution of the License, Development and Commercialization Agreement for Cebranopadol in Greater China by Subsidiaries Hangzhou CONBA and Hong Kong CONBA with AdneurisJul 7
"Zhejiang CONBA Pharmaceutical Co., Ltd."Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026Jul 4
"Zhejiang CONBA Pharmaceutical Co.,Ltd."Announcement on Self-exercise Results of Stock Option Incentive Plan and Share Changes for Q2 2026Jul 2

All Zhejiang Conba Pharmaceutical Co., Ltd. Class A news releases